These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8610976)

  • 1. Mucosal tolerance in a murine model of experimental autoimmune encephalomyelitis.
    Metzler B; Wraith DC
    Ann N Y Acad Sci; 1996 Feb; 778():228-42. PubMed ID: 8610976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity.
    Metzler B; Wraith DC
    Int Immunol; 1993 Sep; 5(9):1159-65. PubMed ID: 7694644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins.
    Sakai K; Zamvil SS; Mitchell DJ; Hodgkinson S; Rothbard JB; Steinman L
    Proc Natl Acad Sci U S A; 1989 Dec; 86(23):9470-4. PubMed ID: 2480602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative analysis of peptides from myelin basic protein binding to the MHC class II protein, I-Au, which confers susceptibility to experimental allergic encephalomyelitis.
    Fugger L; Liang J; Gautam A; Rothbard JB; McDevitt HO
    Mol Med; 1996 Mar; 2(2):181-8. PubMed ID: 8726461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis.
    Ito K; Bian HJ; Molina M; Han J; Magram J; Saar E; Belunis C; Bolin DR; Arceo R; Campbell R; Falcioni F; Vidović D; Hammer J; Nagy ZA
    J Exp Med; 1996 Jun; 183(6):2635-44. PubMed ID: 8676084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of experimental autoimmune encephalomyelitis in Lewis rats by nasal administration of encephalitogenic MBP peptides: synergistic effects of MBP 68-86 and 87-99.
    Liu JQ; Bai XF; Shi FD; Xiao BG; Li HL; Levi M; Mustafa M; Wahren B; Link H
    Int Immunol; 1998 Aug; 10(8):1139-48. PubMed ID: 9723700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes.
    Sharma SD; Nag B; Su XM; Green D; Spack E; Clark BR; Sriram S
    Proc Natl Acad Sci U S A; 1991 Dec; 88(24):11465-9. PubMed ID: 1722335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subtle effects on myelin basic protein-specific T cell responses can lead to a major reduction in disease susceptibility in experimental allergic encephalomyelitis.
    Vowles C; Chan VS; Bodmer HC
    J Immunol; 2000 Jul; 165(1):75-82. PubMed ID: 10861037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MHC class II-regulated central nervous system autoaggression and T cell responses in peripheral lymphoid tissues are dissociated in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis.
    Weissert R; de Graaf KL; Storch MK; Barth S; Linington C; Lassmann H; Olsson T
    J Immunol; 2001 Jun; 166(12):7588-99. PubMed ID: 11390515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell recognition of distinct peptide:I-Au conformers in murine experimental autoimmune encephalomyelitis.
    Huang JC; Han M; Minguela A; Pastor S; Qadri A; Ward ES
    J Immunol; 2003 Sep; 171(5):2467-77. PubMed ID: 12928395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental autoimmune encephalomyelitis-resistant mice have highly encephalitogenic myelin basic protein (MBP)-specific T cell clones that recognize a MBP peptide with high affinity for MHC class II.
    Abromson-Leeman S; Alexander J; Bronson R; Carroll J; Southwood S; Dorf M
    J Immunol; 1995 Jan; 154(1):388-98. PubMed ID: 7527816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of experimental autoimmune encephalomyelitis induction in SJL/J mice by using a peptide with high affinity for IAs molecules.
    Lamont AG; Sette A; Fujinami R; Colón SM; Miles C; Grey HM
    J Immunol; 1990 Sep; 145(6):1687-93. PubMed ID: 1697306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of experimental autoimmune encephalomyelitis by MHC class II binding competitor peptides depends on the relative MHC binding affinity of the disease-inducing peptide.
    Wauben MH; Joosten I; Schlief A; van der Zee R; Boog CJ; van Eden W
    J Immunol; 1994 Apr; 152(8):4211-20. PubMed ID: 7511673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cell recognition in experimental autoimmune encephalomyelitis: prospects for immune intervention with synthetic peptides.
    Wraith DC; Smilek DE; Mitchell DJ; Steinman L; McDevitt HO
    Int Rev Immunol; 1990; 6(1):37-47. PubMed ID: 1715375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amino acid variations at a single residue in an autoimmune peptide profoundly affect its properties: T-cell activation, major histocompatibility complex binding, and ability to block experimental allergic encephalomyelitis.
    Kumar V; Urban JL; Horvath SJ; Hood L
    Proc Natl Acad Sci U S A; 1990 Feb; 87(4):1337-41. PubMed ID: 1689484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of experimental autoimmune encephalomyelitis by administration of cells expressing antigenic peptide covalently linked to MHC class II.
    Weishaupt A; Kreiss M; Gold R; Herrmann T
    J Neuroimmunol; 2004 Jul; 152(1-2):11-9. PubMed ID: 15223233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of oral myelin basic protein and dexamethasone treatment on experimental autoimmune encephalomyelitis.
    Mokhtarian F; Shirazian T; Batuman O; Shi Y
    Ann N Y Acad Sci; 1996 Feb; 778():414-7. PubMed ID: 8611007
    [No Abstract]   [Full Text] [Related]  

  • 18. Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis.
    Vanderlugt CL; Neville KL; Nikcevich KM; Eagar TN; Bluestone JA; Miller SD
    J Immunol; 2000 Jan; 164(2):670-8. PubMed ID: 10623809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimum structural requirements for peptide presentation by major histocompatibility complex class II molecules: implications in induction of autoimmunity.
    Gautam AM; Lock CB; Smilek DE; Pearson CI; Steinman L; McDevitt HO
    Proc Natl Acad Sci U S A; 1994 Jan; 91(2):767-71. PubMed ID: 7507253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A small number of residues in the class II molecule I-Au confer the ability to bind the myelin basic protein peptide Ac1-11.
    Pearson CI; Gautam AM; Rulifson IC; Liblau RS; McDevitt HO
    Proc Natl Acad Sci U S A; 1999 Jan; 96(1):197-202. PubMed ID: 9874795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.